A quantitative structure–activity relationship study of anti-HIV activity of substituted HEPT using nonlinear models by Hadi Noorizadeh et al.
ORIGINAL RESEARCH
A quantitative structure–activity relationship study of anti-HIV
activity of substituted HEPT using nonlinear models
Hadi Noorizadeh • Sami Sajjadifar •
Abbas Farmany
Received: 31 January 2012 / Accepted: 31 January 2013 / Published online: 27 February 2013
 The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract We performed studies on extended series of 79
HEPT ligands (1-[(2-hydroxyethoxy)methyl]-6-(phenyl-
thio)thymine), inhibitors of HIV reverse-transcriptase with
anti-HIV biological activity, using quantitative structure–
activity relationship (QSAR) methods that imply analysis
of correlations and representation of models. A suitable set
of molecular descriptors was calculated, and the genetic
algorithm was employed to select those descriptors which
resulted in the best-fit models. The kernel partial least
square and Levenberg–Marquardt artificial neural network
were utilized to construct the nonlinear QSAR models. The
proposed methods will be of great significance in this
research, and would be expected to apply to other similar
research fields.
Keywords AIDS  Anti-HIV activity  HEPT ligands 
QSAR  Genetic algorithm 
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Introduction
Acquired immune deficiency syndrome or acquired
immunodeficiency syndrome (AIDS) is a disease of the
human immune system caused by the human immunode-
ficiency virus (HIV). This condition would progressively
reduce the effectiveness of the immune system and leaves
individuals susceptible to opportunistic infections and
tumors (Jabs, 2011; Chitra et al., 2011; Ganguli et al.,
2012; Holland et al., 2010; Wachira and Ruger, 2011).
Acquired immunodeficiency syndrome is now a pan-
demic, and it has been the sixth leading cause of death
among people aged 25–44 in the United States since 1995.
The World Health Organization estimated that more than
25 million people worldwide have died from this infection
since the start of the epidemic (Kallings, 2008). In 2009,
AVERT reported that there were 33.3 million people
worldwide living with HIV/AIDS, with 2.6 million new
HIV infections per year and 1.8 million annual deaths due
to AIDS. In 2007, UNAIDS estimated that 33.2 million
people worldwide had AIDS that year, AIDS killed 2.1
million people in the course of that year, including 330,000
children, and moreover 76 % of those deaths occurred in
sub-Saharan Africa. According to UNAIDS 2009 report,
we have had 60 million infected people, 25 million deaths,
and 14 million orphaned children in southern Africa since
the epidemic began (Nagata et al., 2011; Furin et al.,
2012).
Human immunodeficiency virus (HIV) causes AIDS.
The virus attacks the immune system and leaves the body
vulnerable to a variety of life-threatening infections and
cancers. Common bacteria, yeast, parasites, and viruses
which do not ordinarily cause serious diseases in people
with healthy immune systems can cause fatal illnesses in
people with AIDS.
HIV has been found in saliva, tears, nervous system
tissue and spinal fluid, blood, semen (including pre-seminal
fluid, which is the liquid that comes out before ejaculation),
vaginal fluid, and breast milk. However, only blood, semen,
vaginal secretions, and breast milk generally transmits
infection to others (Schmidt, 2011). The virus can be spread
(transmitted) by sexual contact (including oral, vaginal, and
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anal sex), blood [via blood transfusions (now extremely rare
in the U.S.) or needle sharing], exchange between mother
and baby during pregnancy, childbirth, breastfeeding, or
other exposures to one of the above bodily fluids; other
methods of spreading the virus are rare and include acci-
dental needle injury, artificial insemination with infected
donated semen, and organ transplantation with infected
organs. AIDS is not transmitted to a person who donates
blood or organs. However, HIV can be transmitted to a
person receiving blood or organs from an infected donor. To
reduce this risk, blood banks and organ donor programs
screen donors, blood, and tissues thoroughly (Johnston
et al., 2010; Firla˛g-Burkacka et al., 2009).
Although treatments for AIDS and HIV can slow the
course of the disease, there is no known cure or vaccine.
Antiretroviral treatment reduces both the mortality and the
morbidity of HIV infection, but these drugs are expensive,
and routine access to antiretroviral medication is not
available in all countries (Guo and Li, 2011; Fomsgaard
et al., 2011). Due to the difficulty in treating HIV infection,
preventing infection is a key aim in controlling the AIDS
pandemic, with health organizations promoting safe sex
and needle-exchange programs in attempts to slow the
spread of the virus. HIV is transmitted through direct
contact of a mucous membrane or the bloodstream with a
bodily fluid containing HIV, such as blood, semen, vaginal
fluid, preseminal fluid, and breast milk (Self, 2010).
Acquired immunodeficiency syndrome begins with HIV
infection. People infected with HIV may have no symp-
toms for 10 years or longer, but they can still transmit the
infection to others during this symptom-free period. If the
infection is not detected and treated, the immune system
gradually weakens and AIDS develops. People with AIDS
also have an increased risk of developing various cancers
such as Kaposi’s sarcoma, cervical cancer, and cancers of
the immune system known as lymphomas. In addition,
people with AIDS often have systemic symptoms of
infection like fevers, sweats (particularly at night), swollen
glands, chills, weakness, and weight loss (Holmes et al.,
2003). The specific opportunistic infections that AIDS
patients develop depend, in part, on the prevalence of these
infections in the geographic area in which the patient lives.
The initial infection with HIV may produce no symptoms:
some people, however, do experience flu-like symptoms
with fever, rash, sore throat, and swollen lymph nodes,
usually 2–4 weeks after contracting the virus. Some people
with HIV infection stay symptom-free for years between
the time they are exposed to the virus and when they
develop AIDS (Lyons et al., 2011).
An anti-HIV agent can exert its biological activity in
different stages of the viral life cycle inhibiting them.
Studies were limited to those stages and phenomenon that
appear during viral replication: viral binding to the target
cell, viral fusion with the host cell by viral penetration into
the host cell’s membrane, viral uncovering in the host cell,
reverse genomic RNA transcription, integration of the new
viral DNA into the host cell’s chromosomes, provirus
activation producing mRNA, viral detachment from the
host cell, and viral maturation.
Reverse transcription of viral genomic RNA into double
strained DNA by the RT enzyme is essential for HIV
replication. Thus, the inhibition of this essential phase of
HIV life cycle provides the most attractive target in order
to develop a compound with biological anti-HIV potential.
For example, most drugs approved by the FDA for HIV
infection treatment are RT inhibitors. High resolution
electronic microscopy shows that HIV-1 is a 100 nm virus
with a capsule. The external layer is a double lipidic layer
derived from the host cell during maturation and contains
two major viral glycoproteins (gp): the transmembranar
gp41 and outside gp120. There is a protein associated to
the membrane (p 18) which provides the matrix for the
viral structure and is essential for the integrity of the virus.
The matrix surrounds a dense cylindrical characteristic
nucleoid which contains the p24 protein from the capside.
Inside the nucleoid, there are two identical RNA strains;
the viral RNA dependent DNA-polymerase (p66/p55)
called reverse-transcriptase (RT) is related to p9 nucleo-
protein, to p12 integrase protein, and to components of p15
protease, see Fig. 1 (Ganguli et al., 2012; Wachira and
Ruger, 2011; Holmes et al., 2003; Lyon et al., 2011).
By these means, HEPT (1-[(2-hydroxyethoxy)methyl]-
6-(phenylthio)thymine) derivatives can be regarded as non-
nucleosidic reverse transcriptase inhibitors (NNRTI), see
Figs. 2 and 3, and are analogs of the natural substrate.
HEPT derivatives don’t interact with the binding site of the
DNA or RNA-dependent DNA polymerase. Because of this
it is expected that these ligands would not determine side
effects. HEPT ligands interact uncompetitively with an
allosteric site of the enzyme and don’t affect the substrate
binding in a direct way. Actually, NNRTI have a higher
binding affinity to the ligand–enzyme complex than to the
free enzyme. The HEPT ligand–enzyme interaction leads
to enzymatic conformational variations; in other words, the
enzyme’s active site has a decreased affinity to the natural
substrate. This property is valid only regarding the HIV-1
RT; HEPT ligands are inactive against HIV-2 or other
retroviruses. The NNRTI exclusive specificity for the HIV-
1 RT is attributed to the presence—at the level of this
enzyme (and not in the case of other RT or DNA poly-
merases)—of a flexible extreme hydrophobic pocket in
which HEPT derivatives (different from natural substrate
analogs) fit and can be bound (Ji et al., 2007; Wang et al.,
2009; Bajaj et al., 2005).
The term ‘half maximal effective concentration’ (EC50)
refers to the concentration of a drug, antibody, or toxicant,
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which induces a response between the baseline and maximum
after some specified exposure time. It is commonly used as a
measure of a drug’s potency. The EC50 of a graded dose–
response curve represents the concentration of a compound
where 50 % of its maximal effect is observed. The EC50 of a
quantal dose–response curve represents the concentration of a
compound where 50 % of the population exhibits a response,
after specified exposure duration (Luis et al., 2010).
Various partial drugs which have been created would
treat the HIV infection at various stages but no drug has
been found yet to cure. Because of this, we need to com-
prehend the chemicals and mathematical models that could
be applied as an extrapolation model to study the desired
features of an anti-HIV drug. The best mathematical model
that can quantitatively relate the anti-HIV activity with the
structural descriptors is the QSAR model (Quantitative
Structure Activity Relationship). The QSAR analysis has
been done for various groups of compounds and also for
diverse sets of anti-HIV compounds (Goodarzi and Freitas,
2010; Bharate and Singh, 2011; Goodarzi et al., 2009;
Si et al., 2008).
There is a trend to develop QSAR from a variety of
methods. In particular, genetic algorithm (GA) is fre-
quently used as search algorithm for variable selections in
chemometrics and QSAR (Yanmaz et al., 2011). Moreover,
nonlinear statistical treatment of QSAR data is expected to
provide models with better predictive quality as compared
with linear models. In this perspective, artificial neural
network (ANN) modeling has become quite common in the
QSAR field (Afantitis et al., 2011; Zuperl et al., 2011).
Extensive use of ANN, which does not require the
‘‘a priori’’ knowledge of the mathematical form of the
relationship between the variables, largely rests on its
flexibility (functions of any complexity can be approxi-
mated). In recent years, nonlinear kernel-based algorithm
as kernel partial least squares (KPLS) has been proposed
(Postma et al., 2011). KPLS can efficiently compute latent
variables in the feature space by means of nonlinear kernel
functions. Compared to other nonlinear PLS methods, the
main advantage of the kernel-based algorithm is that it does


























































Fig. 3 Typical examples of HEPT (1-[(2-hydroxyethoxy)methyl]-6-
(phenylthio)thymine) derivatives
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not involve nonlinear optimization; thus it essentially
requires only linear algebra which makes it as simple as the
conventional linear PLS. In addition, because of its ability
to use different kernel functions, KPLS can handle a wide
range of nonlinearities (Cao et al., 2011). In the present
study, GA-KPLS and L–M ANN were employed to gen-
erate QSAR models that correlate the structure of HEPT
ligands and inhibitors of HIV reverse-transcriptase (RT),
with anti-HIV biological activity log (1/EC50).
Computational
Data set
The anti-HIV biological activity log (1/EC50) of 79 HEPT
derivatives which were taken from the literature (Duda-
Seiman et al., 2004) has been presented in Table 1. In this
table are given the group of substituents considered on the
general structure of Figs. 2 and 3. Biological activities are
given as log (1/EC50) where EC50 represents the concen-
tration and also produces a 50 % protection of MT-4 cells
against the direct toxic HIV-1 effect.
Computer hardware and software
All calculations were run on a HP laptop computer with an
AMD Turion64X2 processor and a Windows XP operating
system. The optimizations of molecular structures were
done by HyperChem 7.0 and descriptors were calculated by
Dragon Version 3.0 software. Cross validation, GA-KPLS,
L–M ANN and other calculations were performed in the
MATLAB (Version 7, Mathworks, Inc.) environment.
Molecular modeling and theoretical molecular
descriptors
The derivation of theoretical molecular descriptors pro-
ceeds from the chemical structure of the compounds. In
order to calculate the theoretical descriptors, molecular
structures were constructed with the aid of HyperChem
version 7.0. The final geometries were obtained with the
semi-empirical AM1 method in HyperChem program. The
molecular structures were optimized using Fletcher–
Reeves algorithm until the root mean square gradient was
0.01 kcal mol-1. The resulting geometry was transferred
into Dragon program in order to calculate 1,497 descrip-
tors, which was developed by Todeschini et al., (2003).
Genetic algorithm for descriptor selection
To select the most relevant descriptors with GA, the evo-
lution of the population was simulated (Noorizadeh and
Noorizadeh, 2012; Van Dijck and Van Hulle, 2011;
Cse´falvayova´ et al., 2010). Each individual of the popu-
lation, defined by a chromosome of binary values, repre-
sented a subset of descriptors. The number of the genes at
each chromosome was equal to the number of the
descriptors. The population of the first generation was
selected randomly. A gene was given the value of one if its
corresponding descriptor was included in the subset;
otherwise, it was given the value of zero. The number of
the genes with the value of one was kept relatively low to
have a small subset of descriptors (Hao et al., 2011); in
other words, the probability of generating zero for a gene
was set greater. The operators used here were crossover
and mutation. The application probability of these opera-
tors was varied linearly with a generation renewal. For a
typical run, the evolution of the generation was stopped,
when 90 % of the generations had taken the same fitness.
In this paper, size of the population is 30 chromosomes, the
probability of initial variable selection is 5:V (V is the
number of independent variables), crossover is multi Point,
the probability of crossover is 0.5, mutation is multi Point,
the probability of mutation is 0.01, and the number of




An artificial neural network (ANN) with a layered structure
is a mathematical system that stimulates biological neural
network consisting of computing units named neurons and
connections between neurons named synapses (Noorizadeh
and Farmany, 2012; Garkani-Nejad and Ahmadi-Roudi,
2010; Singh et al., 2010). All feed-forward ANN used in
this paper are three-layer networks. Each neuron in any
layer is fully connected with the neurons of a succeeding
layer. Figure 4 shows an example of the architecture of
such ANN. The Levenberg–Marquardt back propagation
algorithm was used for ANN training and the linear func-




Results of the GA-KPLS model
The leave-group-out cross validation (LGO-CV) has been
performed. In this research, a radial basis kernel function,




, was selected as the kernel
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Table 1 The data set, structure, and the corresponding observed log (1/EC50) values
No. R1 R2 R3 X log (1/EC50)EXP
Calibration set
1 Methyl 4-Methylphenylthio 2-Hydroxyethyl O 3.66
2 Methyl 3-Hydroxyphenylthio 2-Hydroxyethyl O 4.09
3 Methyl 2-Methylphenylthio 2-Hydroxyethyl O 4.15
4 Benzyl Phenylthio 2-Hydroxyethyl O 4.37
5 Methyl 3-Methoxyphenylthio 2-Hydroxyethyl O 4.66
6 Methyl 2-Methoxyphenylthio 2-Hydroxyethyl O 4.72
7 Methyl 3-Tertbutylphenylthio 2-Hydroxyethyl O 4.92
8 Methyl 3-Cyanophenylthio 2-Hydroxyethyl O 5.00
9 Methyl Phenylthio 2-Methoxyethyl O 5.06
10 Methyl 3-Methoxycarbonylphenylthio 2-Hydroxyethyl O 5.10
11 Methyl Phenylthio 2-Benzoyloxyethyl O 5.12
12 Methyl Phenylthio 2-Acetyloxyethyl O 5.17
13 2-Phenylethenyl Phenylthio 2-Hydroxyethyl O 5.22
14 Methyl Phenylthio 2-Azidoethyl O 5.24
15 Methyl Phenylthio Butyl O 5.33
16 Ethyl Phenylthio Cyclohexyl O 5.40
17 Propyl Phenylthio 2-Hydroxyethyl O 5.47
18 Methyl Phenylthio Propyl O 5.48
19 Methyl 3-Ethylphenylthio 2-Hydroxyethyl O 5.57
20 Allyl Phenylthio 2-Hydroxyethyl O 5.60
21 Methyl Phenylthio Methyl O 5.68
22 Ethyl Phenylthio Cyclohexyl S 5.79
23 Methyl Phenylthio 2-Chloroethyl O 5.82
24 Methyl Phenylthio Propyl S 5.92
25 Methyl Phenylthio 2-Hydroxyethyl S 6.01
26 Ethyl Phenylthio Cyclohexylmethyl O 6.35
27 Ethyl Phenylthio Isopropyl O 6.47
28 Methyl Phenylthio Ethyl O 6.48
29 Methyl 3,5-Dimethylphenylthio 2-Hydroxyethyl O 6.59
30 Ethyl Phenylthio Isopropyl S 6.66
31 Ethyl Phenylthio 2-hydroxyethyl O 6.92
32 Cyclopropyl Phenylthio Ethyl O 7.00
33 Ethyl Phenylthio 2-Cyclohexylethyl O 7.02
34 Methyl Phenylthio Benzyl O 7.06
35 Ethyl Phenylthio 4-Methylbenzyl S 7.11
36 Isopropyl Phenylthio 2-Hydroxyethyl O 7.20
37 Ethyl 3,5-Dichlorophenylthio 2-Hydroxyethyl S 7.37
38 Ethyl Phenylthio Ethyl S 7.58
39 Ethyl 3,5-Dichlorophenylthio 2-Hydroxyethyl O 7.85
40 Isopropyl Phenylthio Ethyl S 7.89
41 Ethyl Phenylthio 4-Chlorobenzyl S 7.92
42 Ethyl Phenylthio Benzyl S 8.09
43 Ethyl 3,5-Dichlorophenylthio Ethyl O 8.13
44 Isopropyl Phenylthio Benzyl S 8.14
45 Ethyl Phenylthio Benzyl O 8.23
46 Isopropyl 3,5-Dimethylphenylthio 2-Hydroxyethyl S 8.30
47 Isopropyl Phenylthio Benzyl O 8.51
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function with c ¼ rmr2 where r is constant that can be
determined by considering the process to be predicted (here
r set to be 1), m is the dimension of the input space, and r2
is the variance of the data (Kim et al., 2005). It means that
the value of c depends on the system under the study. The
14 descriptors in five latent variables—space chosen by
GA-KPLS feature selection methods—were contained
constitutional descriptors (number of Oxygen atoms (nO)
and number of non-H bonds (nBO)), topological descrip-
tors (centralization (CENT)), geometric descriptors (grav-
itational index G2 (bond-restricted) (G2), 3D Petitjean
shape index (PJI3), and Qxx COMMA2 value/weighted by
atomic van der Waals volumes (QXXv)), 3D-MoRSE
descriptors (3D-MoRSE—signal 09/weighted by atomic
masses (Mor09m)), WHIM descriptors (first component
accessibility directional WHIM index/weighted by atomic
polarizabilities (E1p) and A total size index/weighted by
atomic electrotopological states (As)), atom-centered
fragments (number of terminal primary C(sp3) (nCp),
CH3R/CH4 (C-001) and phenol/enol/carboxyl OH (O-057))
and charge descriptors (relative positive charge (RPCG)
and submolecular polarity parameter (SPP)). The R2 and
RE for training and test sets were (0.861, 0.748) and
(14.37, 23.09), respectively. For the constructed model,
two general statistical parameters were selected to evaluate
the prediction ability of the model for the log (1/EC50). The
Table 1 continued
No. R1 R2 R3 X log (1/EC50)EXP
48 Isopropyl 3,5-Dimethylphenylthio 2-Hydroxyethyl O 8.57
Prediction set
49 Methyl 3-Trifluoromethylphenylthio 2-Hydroxyethyl O 4.35
50 Methyl 3-Chlorophenylthio 2-Hydroxyethyl O 4.89
51 Propyl Phenylthio 2-Hydroxyethyl S 5.00
52 Methyl Phenylthio 2-Hydroxyethyl O 5.15
53 Methyl 3-Fluorophenylthio 2-Hydroxyethyl O 5.48
54 Methyl Phenylthio Methyl S 5.66
55 Methyl 3,5-Dichlorophenylthio 2-Hydroxyethyl O 5.89
56 Ethyl Phenylthio Cyclohexylmethyl S 6.45
57 Ethyl Phenylthio 2-Hydroxyethyl S 6.96
58 Cyclopropyl Phenylthio Ethyl S 7.02
59 Ethyl Phenylthio Ethyl O 7.72
60 Ethyl 3,5-Dichlorophenylthio Ethyl S 7.89
61 Isopropyl Phenylthio Ethyl O 7.99
62 Ethyl 3,5-Dimethylphenylthio 2-Hydroxyethyl S 8.11
63 Ethyl 3,5-Dimethylphenylthio Ethyl O 8.24
64 Ethyl 3,5-Dimethylphenylthio Benzyl O 8.55
Test set
65 Methyl 2-Nitrophenylthio 2-Hydroxyethyl O 3.85
66 Methyl 3-Nitrophenylthio 2-Hydroxyethyl O 4.47
67 Methyl 3-Iodophenylthio 2-Hydroxyethyl O 5.00
68 Methyl 3-Acetylphenylthio 2-Hydroxyethyl O 5.14
69 Methyl 3-Bromophenylthio 2-Hydroxyethyl O 5.24
70 Iodo Phenylthio 2-Hydroxyethyl O 5.44
71 Methyl 3-Methylphenylthio 2-Hydroxyethyl O 5.59
72 Ethenyl Phenylthio 2-Hydroxyethyl O 5.69
73 Methyl Phenylthio 2-Fluoroethyl O 5.96
74 Methyl 3,5-Dimethylphenylthio 2-Hydroxyethyl S 6.66
75 Ethyl Phenylthio 2-Phenylethyl S 7.04
76 Isopropyl Phenylthio 2-Hydroxyethyl S 7.23
77 Ethyl 3,5-Dimethylphenylthio 2-Hydroxyethyl O 7.89
78 Ethyl 3,5-Dimethylphenylthio Benzyl S 8.14
79 Ethyl 3,5-Dimethylphenylthio Ethyl S 8.30
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predicted values of log (1/EC50) are plotted against the
experimental values for training and test sets in Fig. 5.
Consequently, as a result, the number of components
(latent variables) is less than the number of independent
variables in KPLS analysis. The statistical parameters
highest square correlation coefficient leave-group-out cross
validation (R2) and relative error (RE) were obtained for
proposed models. Each of the statistical parameters men-
tioned above was used for assessing the statistical signifi-
cance of the QSAR model. This GA-KPLS approach
currently constitutes the most accurate method for pre-
dicting the anti-HIV biological activity of the drug com-
pounds. The KPLS model uses higher number of
descriptors that allows the model to extract better structural
information from descriptors to result in a lower prediction
error. This suggests that GA-KPLS holds promise for
applications in choosing variables for L–M ANN systems.
This result indicates that the log (1/EC50) of these drugs
possesses some nonlinear characteristics.
Results of the L–M ANN model
With the aim of improving the predictive performance of
nonlinear QSAR model, L–M ANN modeling was per-
formed. The networks were generated using the 14
descriptors appearing in the GA-KPLS models as their
inputs and log (1/EC50) as their output. For ANN genera-
tion, data set was separated into three groups: calibration,
prediction, and test sets. A three-layer network with a
sigmoid transfer function was designed for each ANN.
Before training the networks, the input and output values
were normalized between -1 and 1. Then, the network was
trained using the training set and the back propagation
strategy for optimizing the weights and bias values. The
proper number of nodes in the hidden layer was determined
by training the network with different number of nodes in
the hidden layer. The root-mean-square error (RMSE)
value measures how good the outputs are in comparison
with the target values. It should be noted that for evaluating
the over fitting, the training of the network for the pre-
diction of log (1/EC50) must stop when the RMSE of the
prediction set begins to increase while RMSE of calibration
set continues to decrease. Therefore, training the network
was stopped when overtraining began. All of the above
mentioned steps were carried out using basic back propa-
gation, conjugate gradient, and Levenberge–Marquardt
weight update functions. Accordingly, one can realize that
the RMSE for the training and test sets are minimum when
five neurons were selected in the hidden layer. Finally, the
number of iterations was optimized with the optimum
values for the variables. The R2 and RE for calibration,
prediction, and test sets were (0.916, 0.894, 0.868) and
(9.98, 11.34, 15.29), respectively. The experimental, cal-
culated, relative error and RMSE values log (1/EC50) by
L–M ANN are shown in Table 2. Inspection of the results
reveals a higher R2 and lowers other values parameter for
the training, test, and prediction sets compared with their
counterparts for GA-KPLS. Plots of predicted log (1/EC50)
versus experimental log (1/EC50) values by L–M ANN for
calibration, prediction, and test sets are shown in Fig. 6a, b.
Obviously, there is a close agreement between the exper-
imental and predicted log (1/EC50), and the data represent a
very low scattering around a straight line with respective
slope and intercept close to one and zero. This clearly
shows the strength of L–M ANN as a nonlinear feature
selection method. The key strength of L–M ANN is their
ability to allow for flexible mapping of the selected features
by manipulating their functional dependence implicitly.
The residuals (predicted log (1/EC50) - experimental log
(1/EC50)) obtained by the L–M ANN modeling versus the
experimental log (1/EC50) values are shown in Fig. 7a, b.
As the calculated residuals are distributed on both sides of
the zero line, one may conclude that there is no systematic




















Fig. 5 Plots of predicted log (1/EC50) against the experimental
values by GA-KPLS model
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of these data clearly displays a significant improvement
of the QSAR model consequent to nonlinear statistical
treatment.
Model validation and statistical parameters
The applied internal (leave-group-out cross validation
(LGO-CV)) and external (test set) validation methods were
used for the predictive power of models. In the leave-
group-out procedure, one compound was removed from the
data set, the model was trained with the remaining com-
pounds and used to predict the discarded compound. The
Table 2 Experimental, calculated, relative error, and RMSE values









1 3.66 3.84 4.86 0.18 0.03
2 4.09 4.21 3.02 0.12 0.02
3 4.15 4.52 8.80 0.36 0.05
4 4.37 4.66 6.66 0.29 0.04
5 4.66 3.90 16.31 -0.76 0.11
6 4.72 4.84 2.60 0.12 0.02
7 4.92 4.49 8.84 -0.43 0.06
8 5.00 5.04 0.84 0.04 0.01
9 5.06 5.02 0.89 -0.04 0.01
10 5.10 5.47 7.26 0.37 0.05
11 5.12 5.48 7.10 0.36 0.05
12 5.17 5.14 0.56 -0.03 0.00
13 5.22 5.52 5.74 0.30 0.04
14 5.24 5.40 3.12 0.16 0.02
15 5.33 4.80 10.00 -0.53 0.08
16 5.40 5.00 7.38 -0.40 0.06
17 5.47 5.46 0.10 -0.01 0.00
18 5.48 4.97 9.23 -0.51 0.07
19 5.57 5.27 5.45 -0.30 0.04
20 5.60 5.41 3.44 -0.19 0.03
21 5.68 6.13 7.99 0.45 0.07
22 5.79 5.57 3.73 -0.22 0.03
23 5.82 5.53 4.97 -0.29 0.04
24 5.92 5.84 1.34 -0.08 0.01
25 6.01 6.42 6.85 0.41 0.06
26 6.35 5.95 6.31 -0.40 0.06
27 6.47 6.10 5.72 -0.37 0.05
28 6.48 6.42 0.96 -0.06 0.01
29 6.59 6.00 8.95 -0.59 0.09
30 6.66 6.50 2.40 -0.16 0.02
31 6.92 7.45 7.73 0.53 0.08
32 7.00 7.37 5.23 0.37 0.05
33 7.02 7.56 7.68 0.54 0.08
34 7.06 7.00 0.85 -0.06 0.01
35 7.11 7.54 5.98 0.43 0.06
36 7.20 6.20 13.89 -1.00 0.14
37 7.37 6.73 8.69 -0.64 0.09
38 7.58 7.39 2.50 -0.19 0.03
39 7.85 7.00 10.83 -0.85 0.12
40 7.89 7.86 0.32 -0.03 0.00
41 7.92 8.66 9.39 0.74 0.11
42 8.09 7.83 3.16 -0.26 0.04
43 8.13 7.73 4.95 -0.40 0.06
44 8.14 8.28 1.70 0.14 0.02
45 8.23 8.27 0.47 0.04 0.01









47 8.51 8.49 0.27 -0.02 0.00
48 8.57 8.56 0.08 -0.01 0.00
Prediction set
49 4.35 4.15 4.58 0.20 0.05
50 4.89 4.22 13.72 0.67 0.17
51 5.00 5.60 12.00 -0.60 0.15
52 5.15 5.21 1.17 -0.06 0.02
53 5.48 4.94 9.94 0.54 0.14
54 5.66 5.60 1.05 0.06 0.01
55 5.89 6.30 6.96 -0.41 0.10
56 6.45 6.34 1.65 0.11 0.03
57 6.96 7.01 0.72 -0.05 0.01
58 7.02 7.90 12.54 -0.88 0.22
59 7.72 7.90 2.33 -0.18 0.05
60 7.89 7.70 2.41 0.19 0.05
61 7.99 8.51 6.51 -0.52 0.13
62 8.11 7.73 4.75 0.39 0.10
63 8.24 7.78 5.56 0.46 0.11
64 8.55 8.70 1.75 -0.15 0.04
Test set
65 3.85 3.95 2.62 -0.10 0.03
66 4.47 4.47 0.11 0.00 0.00
67 5.00 5.60 12.00 -0.60 0.15
68 5.14 5.24 1.95 -0.10 0.03
69 5.24 4.85 7.42 0.39 0.10
70 5.44 4.70 13.61 0.74 0.19
71 5.59 6.84 22.36 -1.25 0.32
72 5.69 5.10 10.37 0.59 0.15
73 5.96 6.29 5.52 -0.33 0.08
74 6.66 6.01 9.79 0.65 0.17
75 7.04 6.62 6.02 0.42 0.11
76 7.23 8.01 10.79 -0.78 0.20
77 7.89 6.85 13.14 1.04 0.27
78 8.14 8.62 5.86 -0.48 0.12
79 8.30 8.28 0.30 0.03 0.01
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process was repeated for each compound in the data set.
The predictive power of the models developed on the
selected training set is estimated on the predicted values of
test set chemicals. The data set should be divided into three
new sub-data sets, one for calibration and prediction
(training), and the other one for testing. The calibration set
was used for model generation. The prediction set was
applied to deal with overfitting of the network, whereas test
set, the molecules of which have no role in model building
was used for the evaluation of the predictive ability of the
models for external set.
On the other hand by means of training set, the best
model is found and then, its prediction power is checked by
test set, as an external data set. In this study, from all 79
components, 48 components are in calibration set, 16
components are in prediction set, and 15 components are in
test set).
The result clearly displays a significant improvement of
the QSAR model consequent to nonlinear statistical treat-
ment and a substantial independence of model prediction
from the structure of the test molecule. In the above analysis,
the descriptive power of a given model has been measured by
its ability to predict partition of unknown drugs.
For the constructed models, some general statistical
parameters were selected to evaluate the predictive ability
of the models for log (1/EC50) values. In this case, the
predicted log (1/EC50) of each sample in prediction step was
compared with the experimental acidity constant. The first
statistical parameter was relative error (RE) that shows the
predictive ability of each component, and is calculated as:








The predictive ability was evaluated by the square of the
correlation coefficient (R2) which is based on the prediction










where yi is the experimental log (1/EC50) in the sample i,






























Fig. 6 Plot of predicted log (1/EC50) obtained by L–M ANN against
the experimental values a calibration and prediction set of molecules
































Fig. 7 Plot of residuals obtained by L–M ANN against the exper-
imental log (1/EC50) values a training set of molecules and b for test
set
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is the mean of experimental log (1/EC50) in the prediction
set and n is the total number of samples used in the test set.
The main aim of the present study was to assess the
performances of GA-KPLS and L–M ANN for modeling
the anti-HIV biological activity of drugs. The procedures of
modeling including descriptor generation, splitting of the
data, variable selection, and validation were the same as
those performed for modeling of the log (1/EC50) of HEPT
ligands and RT drugs.
Conclusion
In the current research, two nonlinear methods (GA-KPLS
and L–M ANN) were used to construct a quantitative
relation between the anti-HIV biological activity of HEPT
ligands and RT drugs and their calculated descriptors. The
results obtained by L–M ANN were compared with the
results obtained by GA-KPLS model. The results demon-
strated that L–M ANN was more powerful in the log
(1/EC50) prediction of the drug compounds than GA-
KPLS. A suitable model with high statistical quality and
low prediction errors was eventually derived. This model
could accurately predict the anti-HIV biological activity of
these components that did not exist in the modeling pro-
cedure. It was easy to notice that there was a good prospect
for the L–M ANN application in the QSAR modeling.
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